After a press conference by the current Trump administration on Saturday night, it seems clear: if BioNTech and Moderna submit emergency approval applications for their respective COVID-19 vaccine candidates in the near future, they can expect quick decisions on the applications. In the background – not only in the US, like that yesterday’s message from va-Q-tec shows – already worked feverishly on the distribution logistics for the vaccines.
In the event of approval, Moncef Slaoui announced at the press conference that 20 million vaccinations should take place in December, followed by 20 to 30 million per month from 2021. Slaoui was previously on the Board of Moderna and is Chief Scientific Advisor of the “Operation Warp Speed”The Trump administration.
BioNTechs, together with partner Pfizer, as well as Moderna’s vaccine projects against the pandemic pathogen, the SARS-CoV-2 virus, are considered to be the most advanced projects of this type, which are clinically tested on a wide range of test subjects. BioNTech and Pfizer have already presented good final study data and could submit a registration application in the coming week, while Moderna is only a few days “behind” the duo and will present its clinical trial data in the next few days. Experts like the immunologist Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases in the USA, count on it Similar good data from Moderna’s vaccine as in the study by BioNTech and Pfizer.
At a glance – chart and news: Moderna Inc.